IN8bio (NASDAQ:INAB) Rating Increased to Sell at Wall Street Zen

Wall Street Zen upgraded shares of IN8bio (NASDAQ:INAB) to a sell rating in a research note released on Saturday morning.

Separately, HC Wainwright lowered their price target on shares of IN8bio from $240.00 to $180.00 and set a “buy” rating for the company in a report on Friday, March 14th.

IN8bio Trading Down 26.1%

Shares of INAB stock opened at $3.08 on Friday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.84 and a current ratio of 1.84. The stock has a market capitalization of $279.58 million, a P/E ratio of -4.11 and a beta of 0.18. The company has a 50 day moving average price of $4.56 and a 200 day moving average price of $6.88. IN8bio has a fifty-two week low of $2.82 and a fifty-two week high of $52.20.

IN8bio (NASDAQ:INAB) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($2.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.80) by ($0.30). Equities research analysts predict that IN8bio will post -0.56 EPS for the current fiscal year.

Hedge Funds Weigh In On IN8bio

Large investors have recently bought and sold shares of the company. BIOS Capital Management LP purchased a new position in shares of IN8bio in the 4th quarter valued at about $2,212,000. AIGH Capital Management LLC increased its holdings in shares of IN8bio by 269.7% in the 4th quarter. AIGH Capital Management LLC now owns 6,191,865 shares of the company’s stock valued at $1,593,000 after purchasing an additional 4,517,227 shares in the last quarter. Franklin Resources Inc. purchased a new position in shares of IN8bio in the 4th quarter valued at about $1,465,000. Alyeska Investment Group L.P. increased its holdings in shares of IN8bio by 1,064.5% in the 4th quarter. Alyeska Investment Group L.P. now owns 5,063,291 shares of the company’s stock valued at $1,302,000 after purchasing an additional 4,628,482 shares in the last quarter. Finally, Sigma Planning Corp increased its holdings in shares of IN8bio by 22.3% in the 4th quarter. Sigma Planning Corp now owns 1,041,380 shares of the company’s stock valued at $268,000 after purchasing an additional 190,100 shares in the last quarter. Hedge funds and other institutional investors own 92.05% of the company’s stock.

IN8bio Company Profile

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.